Telix Pharmaceuticals guided FY26 revenue above $1 billion after a 7% sequential revenue gain. But the stock fell 1.79%. The ASX 200 dropped 0.29%.
Telix Pharmaceuticals (ASX:TLX) on Tuesday reported a 7% sequential revenue increase for the quarter ended June 30, up 21% from a year earlier. The company told shareholders it expects FY26 revenue and other income to exceed $1 billion, tracking at the upper end of a $950M-$970M guidance range, plus $40 million from Regeneron. Despite the solid top-line news, the stock fell 1.79% to $14.83.
Larvotto Resources (ASX:LRV) was also active on the forums after it started staged commissioning of the minerals processing facility at the Hillgrove mine in South Australia. Managing Director Ron Heeks said first ore is being crushed and placed in the fine ore bin, ready to feed the grinding circuit. “The commencement of commissioning is a defining milestone for Larvotto and reflects the significant progress made over the past twelve months since the plant refurbishment started,” Heeks said. LRV traded down 3.13% to 6.2¢ by lunch.
Evion Group (ASX:EVG) jumped after its Maniry graphite project became the first critical minerals project to receive mining permits in Madagascar under the new mining code. The grant converts the company's remaining exploration permits and secures tenure across all Maniry project areas defined in the feasibility study. The mining permits were finalized with the signing of formal CSR mining contracts; a decree notice is expected this week.
The ASX 200 fell 25.9 points, or 0.29%, on the session.
Telix carries an Alpha Score of 72 out of 100, a moderate rating, in the healthcare sector. The full TLX stock page includes the proprietary score and key metrics.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.